<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520297</url>
  </required_header>
  <id_info>
    <org_study_id>CP130-2004</org_study_id>
    <nct_id>NCT02520297</nct_id>
  </id_info>
  <brief_title>A Pilot Study of TRV130 for the Treatment of Fracture Pain</brief_title>
  <official_title>A Phase 2, Open-label Pilot Study of TRV130 for the Treatment of Moderate to Severe Acute Pain Associated With Long Bone Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevena Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kestrel Biologic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trevena Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the analgesic efficacy of TRV130 for moderate to severe&#xD;
      acute pain in patients presenting to the emergency department (ED) with a suspected/known,&#xD;
      unilateral, closed long bone fracture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the analgesic efficacy of TRV130 for the treatment of&#xD;
      moderate to severe acute pain associated with a long bone fracture in patients presenting to&#xD;
      the ED. The safety and tolerability of TRV130 will also be evaluated in this open-label pilot&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 20, 2015</start_date>
  <completion_date type="Actual">October 23, 2015</completion_date>
  <primary_completion_date type="Actual">October 23, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Achieving Clinical Response, Defined as Achieving a NPRS &lt;= 3, Without Requiring Rescue Pain Medication.</measure>
    <time_frame>3-hours</time_frame>
    <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Weighted Average Change in NPRS</measure>
    <time_frame>From baseline to 30 minutes, to 1 hour, to 2 hours and to 3 hours</time_frame>
    <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First NPRS &lt;= 3</measure>
    <time_frame>3-hours</time_frame>
    <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>3-hours</time_frame>
    <description>Safety assessments include adverse events, vital sign measurements, physical examination findings, and clinical laboratory assessments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>TRV130</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: TRV130</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV130</intervention_name>
    <description>Drug</description>
    <arm_group_label>TRV130</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years, inclusive&#xD;
&#xD;
          -  Has a suspected/known, unilateral, closed fracture of either: radius, ulna (or both)&#xD;
             OR tibia, fibula (or both) BUT not fractures in more than 1 extremity&#xD;
&#xD;
          -  Able to understand and comply with study procedures and requirements, and provide&#xD;
             written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant concomitant head, chest, or abdominal trauma&#xD;
&#xD;
          -  Multiple extremity trauma&#xD;
&#xD;
          -  Open fracture&#xD;
&#xD;
          -  Clinically significant medical condition or history of such condition that may place&#xD;
             the patient at an unacceptable risk in the trial, may interfere with the&#xD;
             interpretation of efficacy, safety, or tolerability data obtained in the trial, or may&#xD;
             interfere with the absorption, distribution, metabolism, or excretion of drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Indiana University</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trevena, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2015</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 7, 2020</results_first_posted>
  <disposition_first_submitted>July 7, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>July 7, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 11, 2017</disposition_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Long bone</keyword>
  <keyword>Fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TRV130</title>
          <description>Drug: TRV130</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TRV130</title>
          <description>Drug: TRV130</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Achieving Clinical Response, Defined as Achieving a NPRS &lt;= 3, Without Requiring Rescue Pain Medication.</title>
        <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
        <time_frame>3-hours</time_frame>
        <population>Study terminated early. Primary outcome not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>TRV130</title>
            <description>Drug: TRV130</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Achieving Clinical Response, Defined as Achieving a NPRS &lt;= 3, Without Requiring Rescue Pain Medication.</title>
          <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
          <population>Study terminated early. Primary outcome not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Weighted Average Change in NPRS</title>
        <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
        <time_frame>From baseline to 30 minutes, to 1 hour, to 2 hours and to 3 hours</time_frame>
        <population>Study terminated early. Secondary outcome not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>TRV130</title>
            <description>Drug: TRV130</description>
          </group>
        </group_list>
        <measure>
          <title>Time Weighted Average Change in NPRS</title>
          <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
          <population>Study terminated early. Secondary outcome not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First NPRS &lt;= 3</title>
        <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
        <time_frame>3-hours</time_frame>
        <population>Study terminated early. Secondary outcome not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>TRV130</title>
            <description>Drug: TRV130</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First NPRS &lt;= 3</title>
          <description>Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours</description>
          <population>Study terminated early. Secondary outcome not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessments</title>
        <description>Safety assessments include adverse events, vital sign measurements, physical examination findings, and clinical laboratory assessments.</description>
        <time_frame>3-hours</time_frame>
        <population>Study terminated early. Secondary outcome not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>TRV130</title>
            <description>Drug: TRV130</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessments</title>
          <description>Safety assessments include adverse events, vital sign measurements, physical examination findings, and clinical laboratory assessments.</description>
          <population>Study terminated early. Secondary outcome not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TRV130</title>
          <description>Drug: TRV130</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early due to lack of enrollment. Analyses for the primary and secondary outcomes were not completed. No mortalities, serious adverse events, or adverse events were reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kelly Arscott</name_or_title>
      <organization>Trevena, Inc.</organization>
      <phone>6103548840</phone>
      <email>karscott@trevena.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

